All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129

Leukemia Research

Volumn 37, Issue 7, 2013, Pages 795-801

  Douer, Dan ^a   Zickl, Lynette N ^b   Schiffer, Charles A ^c   Appelbaum, Fredrick R ^d   Feusner, James H ^e   Shepherd, Lois ^f   Willman, Cheryl L ^g   Bloomfield, Clara D ^h   Paietta, Elisabeth ⁱ   Gallagher, Robert E ⁱ   Park, Jae H ^a   Rowe, Jacob M ^j   Wiernik, Peter H ^k   Tallman, Martin S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CHILDREN S HOSPITAL OAKLAND   (United States)

^f QUEEN S UNIVERSITY   (Canada)

^g UNIVERSITY OF NEW MEXICO   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ MONTEFIORE MEDICAL CENTER   (United States)

^j SHAARE ZEDEK MEDICAL CENTER   (Israel)

^k BETH ISRAEL MEDICAL CENTER   (United States)

more..

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Late relapse

Indexed keywords

CYTARABINE; DAUNORUBICIN; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL OBSERVATION; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NORTH AMERICA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; TRETINOIN; YOUNG ADULT;

EID: 84878516956     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.03.001     Document Type: Article

References (33)

1. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L. Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
2. Castaigne S., Chomienne C., Daniel M.T., Ballerini P., Berger R., Fenaux P., et al. All trans retinoic acid as a differentiating therapy for acute promyelocytic leukemias I. Clinical results. Blood 1990, 76:1704-1709.
3. Wanell R.P., Frankel S.R., Miller W., Scheinberg D.A., Itri L.M., Hittelman W.H., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans retinoic acid). N Engl J Med 1991, 324:1385-1393.
4. Melnick A., Licht J.D. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999, 93:3167-3215.
5. Nasr R., Lallemand-Breitenbach L., Zhu J., Marie-Claude Guillemin M.-C., de Thé H. Therapy induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res 2009, 15:6321-6326.
6. Fenaux P., Le Deley M.C., Castaigne S., Archimbaud E., Chomienne C., Link H., et al. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia, results of a multicenter randomized trial. Blood 1993, 82:3241-3249.
7. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A., et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337:1021-1028.
8. Fenaux P., Chastang C., Chevret S., Sanz M., Dombret H., Archimbaud E., et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999, 94:1192-1200.
9. Burnett A.K., Grimwade D., Solomon E., Wheatley K., Goldstone A.H. On behalf of the MRC adult leukaemia working party, presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999, 93:4131-4143.
10. Kanamaru A., Takemoto Y., Tanimoto M., Murakami H., Asou N., Kobayashiet T., et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia, Japan adult leukemia study group. Blood 1995, 85:1202-1206.
11. Sanz M.A., Lo-Coco F., Martin G., Avvisati G., Rayón C., Barbui T., et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000, 96:1247-1252.
12. Lengfelder E., Reichert A., Schoch C., Haase D., Haferlach T., Löffler H., et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia 2000, 14:1362-1370.
13. Lo-Coco F., Avvisati G., Vignetti M., Breccia M., Gallo E., Rambaldi A., et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults patients younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010, 116:3171-3179.
14. Avvisati G., Lo-Coco F., Paoloni F.P., Petti M.C., Diverio D., Vignetti M., et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011, 117:4716-4725.
15. Fenaux P., Castaigne S., Dombret H., Archimbaud E., Duarte M., Morel P., et al. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute romyelocytic leukemia: a pilot study on 26 cases. Blood 1992, 80:2176-2218.
16. Sanz M.A., Grimwade, Tallman M.S., Lowenberg B., Fenaux P., Estey E.H., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European leukemianet. Blood 2009, 113:1875-1891.
17. Fenaux P., Chevret S., Guerci A., Fegueux N., Dombret H., Thomas X., et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia European APL group. Leukemia 2000, 14:1371-1377.
18. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Woodset W.G., et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American intergroup protocol. Blood 2002, 100:4298-4302.
19. Adès L., Guerci A., Raffoux E., Sanz M., Chevallier P., Lapusan S., et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL group experience. Blood 2010, 115:1690-1696.
20. Kelaidi C., Ades L., Chevret S., Sanz M., Guerci A., Thomas X., et al. Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline-based chemotherapy: the European APL group experience (APL 91 and APL 93 trials). Leukemia 2006, 20:905-907.
21. Ravandi F., Estey E., Jones D., Faderl S., O'Brien S., Fiorentino J., et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009, 27:504-510.
22. Powell B.L., Moser B., Stock W., Gallagher R.E., Willman C.L., Stone R.M., et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American leukemia intergroup study C9710. Blood 2010, 116:3751-3757.
23. Bennett J.M., Young M.L., Andersen J.W., Cassileth P.A., Tallman M.S., Paietta E., et al. Cancer. Long-term survival in acute myeloid leukemia: the Eastern cooperative oncology group experience. Cancer 1997, 80(Suppl 11):2205-2209.
24. Agresti A. Categorical data analysis 1990, John Wiley & Sons, New York.
25. Kaplan E., Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958, 53:457.
26. Sanz M.A., Montesinos P., Vellenga E., Rayón C., de la Serna J., Parody R., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Blood 2008, 112:3130-3134.
27. Lengfelder E., Haferlach C., Saussele S., Haferlach T., Schultheis B., Schnittger S., et al. High dose ARA-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 2009, 23:2248-2258.
28. Powell B.L., Moser B.K., Stock W., et al. Adding mercaptopurine and methotrexate to alternate week ATRA maintenance therapy does not improve the outcome for adults with acute promyelocytic leukemia (APL) in first remission: results from North American leukemia intergroup trial c9710. Blood 2011, 118(118). (abstr 258).
29. Marty M., Ganem G., Fischer J., Flandrin G., Berger R., Schaison G., et al. Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin. Nouv Rev Fr Hematol 1984, 26:371-378.
30. Avvisati G., Petti M.C., Lo-Coco F., Vegna M.L., Amadori S., Baccarani M., et al. GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian cooperative group, induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002, 100:3141-3147.
31. Gallagher R.E., Schachter-Toarz E.L., Zhou D.C., Ding W., Kim S.H., Sankoorikal B.J., et al. Relapse of acute promyelocytic leukemia with PML-RARa mutant subclones independent of proximate all-trans retinoic acid selection pressure. Leukemia 2006, 20:556-562.
32. Park J.H., Qiao B., Panageas K.S., Schymura M.J., Jurcic J.G., Rosenblat T.L., et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011, 118:1248-1254.
33. Altman J.K., Rademaker A., Cull E., Weitner B., Ofran Y., Rosenblat T., et al. Administration of all-trans retinoic acid (ATRA) to newly diagnosed patients (pts) with acute promyelocytic leukemia (APL) is delayed even at experienced centers and associated with an increased early death rate (EDR): a retrospective analysis of 205 pts. Blood 2011, 118(429). (abstr 942).